Drug Discovery
By
Is Novartis’ $1.4 Billion Acquisition of Tourmaline Bio a Game-Changer for Cardiovascular Inflammation Therapies?
Key Highlights A $1.4 Billion Bet on Cardiovascular Innovation Novartis announced its agreement to acquire Tourmaline Bio for…
Could Merck and Daiichi Sankyo’s 48% Response Rate with Ifinatamab Deruxtecan Redefine Treatment for Small Cell Lung Cancer?
Key Highlights Promising Phase 2 Data Signals Breakthrough PotentialResults from the IDeate-Lung01 trial demonstrated compelling clinical activity in…
Could Arrowhead’s $2.2B+ RNAi Collaboration with Novartis Redefine the Future of Parkinson’s and Synucleinopathies?
Key Highlights Strategic SignificanceFor Arrowhead, the deal represents its largest CNS collaboration to date, validating the TRiM™ platform’s…
Could Servier’s $450M Fragile X Acquisition Redefine Its Neurology Strategy?
Key Highlights Strategic Fit for ServierThis marks Servier’s first neurology asset acquisition, aligned with its 2030 strategy to…
Inductive Bio and Amgen Collaborate With ARPA-H to Advance AI-Based Alternatives to Animal Toxicology Testing
United States Inductive Bio, a New York–based artificial intelligence company focused on drug discovery, has been awarded up…
Amgen Takes Steps With U.S. Government to Reduce Prescription Drug Costs for American Patients
Thousand Oaks, California Amgen announced that it is working with the U.S. government on new measures aimed at…
